Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Disruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation

AA. Wurm, P. Zjablovskaja, M. Kardosova, D. Gerloff, D. Bräuer-Hartmann, C. Katzerke, JU. Hartmann, T. Benoukraf, S. Fricke, N. Hilger, AM. Müller, M. Bill, S. Schwind, DG. Tenen, D. Niederwieser, M. Alberich-Jorda, G. Behre,

. 2017 ; 8 (1) : 46. [pub] 20170629

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016509

Transcription factor C/EBPα is a master regulator of myelopoiesis and its inactivation is associated with acute myeloid leukemia. Deregulation of C/EBPα by microRNAs during granulopoiesis or acute myeloid leukemia development has not been studied. Here we show that oncogenic miR-182 is a strong regulator of C/EBPα. Moreover, we identify a regulatory loop between C/EBPα and miR-182. While C/EBPα blocks miR-182 expression by direct promoter binding during myeloid differentiation, enforced expression of miR-182 reduces C/EBPα protein level and impairs granulopoiesis in vitro and in vivo. In addition, miR-182 expression is highly elevated particularly in acute myeloid leukemia patients with C-terminal CEBPA mutations, thereby depicting a mechanism by which C/EBPα blocks miR-182 expression. Furthermore, we present miR-182 expression as a prognostic marker in cytogenetically high-risk acute myeloid leukemia patients. Our data demonstrate the importance of a controlled balance between C/EBPα and miR-182 for the maintenance of healthy granulopoiesis.C/EBPα is a critical transcription factor involved in myelopoiesis and its inactivation is associated with acute myeloid leukemia (AML). Here the authors show a negative feedback loop between C/EBPα and miR-182 and identify this miRNA as a marker of high-risk AML.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016509
003      
CZ-PrNML
005      
20180523130844.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-017-00032-6 $2 doi
035    __
$a (PubMed)28663557
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wurm, Alexander Arthur $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
245    10
$a Disruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation / $c AA. Wurm, P. Zjablovskaja, M. Kardosova, D. Gerloff, D. Bräuer-Hartmann, C. Katzerke, JU. Hartmann, T. Benoukraf, S. Fricke, N. Hilger, AM. Müller, M. Bill, S. Schwind, DG. Tenen, D. Niederwieser, M. Alberich-Jorda, G. Behre,
520    9_
$a Transcription factor C/EBPα is a master regulator of myelopoiesis and its inactivation is associated with acute myeloid leukemia. Deregulation of C/EBPα by microRNAs during granulopoiesis or acute myeloid leukemia development has not been studied. Here we show that oncogenic miR-182 is a strong regulator of C/EBPα. Moreover, we identify a regulatory loop between C/EBPα and miR-182. While C/EBPα blocks miR-182 expression by direct promoter binding during myeloid differentiation, enforced expression of miR-182 reduces C/EBPα protein level and impairs granulopoiesis in vitro and in vivo. In addition, miR-182 expression is highly elevated particularly in acute myeloid leukemia patients with C-terminal CEBPA mutations, thereby depicting a mechanism by which C/EBPα blocks miR-182 expression. Furthermore, we present miR-182 expression as a prognostic marker in cytogenetically high-risk acute myeloid leukemia patients. Our data demonstrate the importance of a controlled balance between C/EBPα and miR-182 for the maintenance of healthy granulopoiesis.C/EBPα is a critical transcription factor involved in myelopoiesis and its inactivation is associated with acute myeloid leukemia (AML). Here the authors show a negative feedback loop between C/EBPα and miR-182 and identify this miRNA as a marker of high-risk AML.
650    _2
$a zvířata $7 D000818
650    _2
$a western blotting $7 D015153
650    _2
$a proteiny vázající zesilovač transkripce CCAAT $x genetika $x metabolismus $7 D022762
650    _2
$a buněčná diferenciace $x genetika $7 D002454
650    12
$a granulocyty $7 D006098
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x genetika $x metabolismus $x mortalita $7 D015470
650    _2
$a leukopoéza $x genetika $7 D019891
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zjablovskaja, Polina $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, 142 20, Czech Republic.
700    1_
$a Kardosova, Miroslava $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, 142 20, Czech Republic.
700    1_
$a Gerloff, Dennis $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Bräuer-Hartmann, Daniela $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Katzerke, Christiane $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Hartmann, Jens-Uwe $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Benoukraf, Touati $u Cancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.
700    1_
$a Fricke, Stephan $u Fraunhofer Institute for Cell Therapy and Immunology, Perlickstraße 1, Leipzig, 04103, Germany.
700    1_
$a Hilger, Nadja $u Fraunhofer Institute for Cell Therapy and Immunology, Perlickstraße 1, Leipzig, 04103, Germany.
700    1_
$a Müller, Anne-Marie $u Fraunhofer Institute for Cell Therapy and Immunology, Perlickstraße 1, Leipzig, 04103, Germany.
700    1_
$a Bill, Marius $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Schwind, Sebastian $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Tenen, Daniel G $u Cancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore. Harvard Stem Cell Institute, Harvard Medical School, 3 Blackfan Circle, Boston, MA, 02115, USA.
700    1_
$a Niederwieser, Dietger $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany.
700    1_
$a Alberich-Jorda, Meritxell $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, 142 20, Czech Republic.
700    1_
$a Behre, Gerhard $u Division of Hematology and Oncology, Leipzig University Hospital, Johannisallee 32a, Leipzig, 04103, Germany. Gerhard.Behre@medizin.uni-leipzig.de.
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 8, č. 1 (2017), s. 46
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28663557 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180523131029 $b ABA008
999    __
$a ok $b bmc $g 1300133 $s 1013349
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 1 $d 46 $e 20170629 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options